Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
Operating Expenses Reduction: Reduced by $500 million compared to Q1 2023. Net Product Sales: $1.8 billion in the third quarter. Cost of Sales: $514 million, representing 28% of net product sales for the quarter. R&D Expenses: $1.1 billion in Q3 2024, a 2% year-over-year decline. SG&A Expenses: $281 million, a 36% year-over-year reduction. U.S. Market Share: 40% share of retail shots in arms for the COVID vaccine. RSV Vaccine Sales: $10 million in Q3. Full-Year Product Sales Guidance: $3 billion to $3.5 billion. International Sales: $0.6 billion in the third quarter. Income Tax: $8 million for the third quarter. Earnings Per Share: $0.03 for the quarter. Warning! GuruFocus has detected 5 Warning Signs with MRNA. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Moderna Inc ( NASDAQ:MRNA ) reported $1.9 billion in revenue for the third quarter, with a net income of $13 million
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- U.S. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Market Research: Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2030 [Yahoo! Finance]Yahoo! Finance
- Moderna Stock Down 39% in Three Months: Buy the Dip or Wait? [Yahoo! Finance]Yahoo! Finance
- Moderna, Inc. (NASDAQ: MRNA) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $41.00 price target on the stock.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $59.00 to $45.00. They now have an "underweight" rating on the stock.MarketBeat
MRNA
Earnings
- 11/7/24 - Beat
MRNA
Sec Filings
- 12/10/24 - Form 4
- 12/9/24 - Form 144
- 12/6/24 - Form 4
- MRNA's page on the SEC website